Summary
[Chengda Pharmaceutical receives a letter of concern: requiring self-examination to indicate whether there is any information disclosure violation]Shenzhen Stock Exchange issued a letter of concern to Chengda Pharmaceutical, requesting to publicly disclose the specific time, company and company for the termination of the PF-07304814 global clinical development plan in conjunction with Pfizer The specific situation of the pharmaceutical intermediate PF-07304814 order from July 2021 to the present, indicating that the company’s reply and announcement did not prompt Pfizer to terminate the clinical development of PF-07304814, and whether the information disclosed is true, accurate and complete. (Interface News)
On the evening of February 17, the management department of the Shenzhen Stock Exchange Growth EnterpriseChengda PharmaceuticalIssue a letter of concern, requesting a combinationPfizerPublicly disclose the specific time for the termination of the global clinical development plan of PF-07304814, the specific situation of the company’s order for the pharmaceutical intermediate PF-07304814 from July 2021 to the present, and explain the company’s response andannouncementNot promptedPfizerThe reasons for terminating the clinical development of PF-07304814, whether the information disclosure is true, accurate and complete; combined with the responses to the above questions, self-examination to explain whether there is a violation of information disclosure, whether there is active catering to market hotspots, hyping company stock prices, or cooperatingshareholdersituation of reduction.
(Article source: Interface News)